Ozmosi | OCU-200 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

OCU-200

Alternative Names: ocu-200, ocu 200, ocu200
Clinical Status: Active
Latest Update: 2025-12-03
Latest Update Note: Clinical Trial Update

Product Description

OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD). (Sourced from: https://ir.ocugen.com/news-releases/news-release-details/ocugen-presents-new-preclinical-ocu200-data-association-research)

Mechanisms of Action: VEGF Binder

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ocugen
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OCU-200

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Macular Edema

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05802329

 DME

P1

Recruiting

Macular Edema

2026-07-31

50%

2025-12-04

Patient Enrollment|Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

03/18/2025

News Article

 Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

01/16/2025

News Article

 Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

10/28/2024

News Article

 Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

10/09/2024

News Article

 Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions